Search
Favorite Blogs
The Alice in Wonderland En Banc Decision by the Federal Circuit in CLS Bank v. Alice
John Kong | May 13, 2013
CLS Bank v. Alice Corporation (en banc)May 10, 2013
After the Federal Circuit issued its en banc decision on May 10, 2013 in CLS Bank v. Alice Corp, the patent owner Alice Corp must be feeling like Alice in Alice in Wonderland, bewildered and frightened by the fantastical situation in which they find themselves:
(1) “bewildered” because an equally divided Federal Circuit affirmed the district court’s holding that Alice’s claimed system to tangible machine components including a first party device, a data storage unit, a second party device, a computer, and a communications controller, programmed with specialized functions consistent with detailed algorithms disclosed in the patent, constitutes a patent ineligible “abstract idea;”
(2) “frightened” because, as Judge Moore puts it, “this case is the death of hundreds of thousands of patents, including all business method, financial system, and software patents as well as many computer implemented and telecommunications patents” (Moore Op. at 2); and
(3) “fantastical” because, as Judge Newman puts it, the en banc court was tasked to provide objective standards for 35 USC §101 patent-eligibility, but instead has “propounded at least three incompatible standards, devoid of consensus, serving to add to the unreliability and cost of the [patent] system…[such that] the only assurance is that any successful innovation is likely to be challenged in opportunistic litigation, whose result will depend on the random selection of the panel” (Newman Op. at 1-2).
Tags: 101 > abstract ideas > Alice > CLS Bank > computer patents > johnkong > patent eligibility > patentable subject matter > preemption > software patents > §101
CAFC Reverses Trial Court’s Indefiniteness Ruling
Scott Daniels | May 9, 2013
Biosig Instruments v. Nautilus
April 26, 2013
Panel: Wallach, Schall and Newman. Opinion by Wallach. Concurrence by Schall.
Summary
The Court of Appeals for the Federal Circuit rarely finds patent claims to be so indefinite that the they are invalid under 35 U.S.C. § 112, ¶ 2. This historical proclivity was on display last in the CAFC’s decision in Biosig Instruments V. Nautilus. There, the Court reversed a summary judgment of invalidity for indefiniteness, concluding that the claim was “amenable to construction” and not ‘insolubly ambiguous.”
Tags: claim construction > indefiniteness > ScottDaniels
If Alleged Infringer Doesn’t Cross-Appeal Validity of Narrowly Interpreted Claim, He May Not Challenge Validity of Later Broadly Construed Claim
Sadao Kinashi | May 8, 2013
Lazare Kaplan Int’l, Inc. v. Photoscribe Techs., Inc.,
April 19, 2013
Panel: Lourie, Dyk and Reyna. Opinion by Lourie. Dissent by Dyk.
Summary
Based on narrow claim construction, the district court issued a prior judgment that patent claims were valid but not infringed either literally or under the doctrine of equivalents. Lazare Kaplan (Patentee) appealed the judgment of non-infringement. But Photoscribe (Alleged Infringer) did not cross-appeal the judgment of validity. On appeal, CAFC broadly interpreted the claims and vacated the judgments of no infringement. The issue of infringement was remanded to the district court.
On remand, Photoscribe moved for summary judgment of invalidity based on the CAFC’s broad claim construction, and moved for relief from the district court’s prior judgment of validity under Rule 60(b). The district court granted both of Photoscribe’s motions. Lazare Kaplan appealed. CAFC reversed both district court decisions holding that the district court abused its discretion by granting relief under Rule 60(b).
地裁は、先の判決で、クレームを狭く解釈し、特許クレームは有効だが、侵害はないと判決した。特許権者Lazare Kaplan社は非侵害判決を不服として控訴したが、被疑侵害者Photoscribe社は、特許有効の判決に関して控訴しなかった。控訴審でCAFCはクレームを広く解釈し、非侵害判決を破棄し、地裁に差戻した。
差戻審で、Photoscribe社は、CAFCの解釈に基づいて特許クレームの無効を主張し、一方、特許有効の確定判決に関し、それに拘束されない連邦民事訴訟規則60(b)に基づく救済を求めた。地裁はPhotoscribe社の両方の申立てを認めた。CAFCは地裁が規則60(b)に基づく救済を認めたことは裁量権を逸脱するとし、また、特許クレーム無効判決を破棄した。
Tags: appeal > cross-appeal > rule 60(b) > SadaoKinashi
Clear and Unmistakeable Evidence of a Disclaimer Found in Response to Enablement Rejection
Kumiko Ide | April 24, 2013
Biogen Idec, Inc., et al. v. GlaxoSmithKline LLC, et al.
April 16, 2013
Panel: Dyk, Plager, Reyna. Opinion by Reyna. Dissent by Plager.
Summary
During prosecution of the patent, applicants responded to the examiner’s enablement rejection, wherein they failed to challenge the examiner’s understanding of the crucial terms, and limited their invention to what the examiner believed their specification enabled. The CAFC affirmed the district court’s narrow claim interpretation of the term “anti-CD20 antibody” based on prosecution history disclaimer.
実施可能要件を満たしていないとして発せられた拒絶通知に対して、出願人は、審査官の理解に対して反論することなく、明細書により実施可能であると審査官が判断したものに発明を限定するような主張を行った。よって、「anti-CD20 antibody」という用語について、狭いクレーム解釈を容認した地裁の判断は誤りでなかったとCAFCは判示した。
Tags: claim construction > disclaimer > estoppel > KumikoIde > prosecution disclaimer > prosecution history disclaimer > prosecution history estoppel